Calendrier des promotions GRAIL, LLC
Calendrier avancé
Graphique simple
À propos de l'entreprise GRAIL, LLC
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. plus de détailsGrade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 0 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -32.8 | 0 |
| ROE | 0 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 0 | 10 |
| Debt/Ratio | 0 | 10 |
| Debt/Equity | 0.0734 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 67.61 | 8 |
| Rentabilité Ebitda, % | 0 | 0 |
| Rentabilité EPS, % | 424.46 | 10 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 14.96 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 14.96 $ | 14.96 $ | 14.96 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.30d | 14.96 $ | 14.96 $ | 14.96 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.90d | 14.96 $ | 14.96 $ | 14.96 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.180d | 14.96 $ | 14.96 $ | 14.96 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.1y | 14.96 $ | 13.9 $ | 20.32 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.3y | 0 $ | 13.66 $ | 20.32 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0 $ | 13.66 $ | 20.32 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 13.66 $ | 20.32 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 14.96 $ | 14.96 $ | 14.96 $ | 0 % | 0 % | 0 % |
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Robert P. Ragusa | Chief Executive Officer | 1960 (65 années) | |
| Dr. Joshua J. Ofman M.D., M.S.H.S | President | 1965 (60 années) | |
| Mr. Aaron Freidin | Chief Financial Officer | ||
| Mr. Paul Ciccolella | Senior VP of Global Development & Operations | ||
| Ms. Amoolya Singh Ph.D. | Senior VP of Research & Chief Scientific Officer | ||
| Mr. Abram Barth J.D., M.P.H. | General Counsel | ||
| Ms. Julie Currie | Chief People Officer | ||
| Mr. Rodger Currie | VP and Head of Government Affairs & Alliance Development | ||
| Mr. Gautam K. Kollu | Chief Commercial Officer | 1974 (51 année) | |
| Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng | President Biopharma Business & Europe |
Informations sur l'entreprise
Adresse: United States, Menlo Park, 1525 O’Brien Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://grail.com
Site web: https://grail.com
